Article
Hematology
Uday R. Popat, Oren Pasvolsky, Roland Bassett Jr, Rohtesh S. Mehta, Amanda Olson, Julianne Chen, Amin M. Alousi, Gheath Al-Atrash, Qaiser Bashir, Alison M. Gulbis, Chitra M. Hosing, Jin S. Im, Partow Kebriaei, Issa Khouri, David Marin, Yago Nieto, Betul Oran, Neeraj Saini, Terri Lynn Shigle, Samer A. Srour, Jeremy L. Ramdial, Katayoun Rezvani, Muzaffar H. Qazilbash, Borje S. Andersson, Richard E. Champlin, Elizabeth J. Shpall
Summary: A fractionated myeloablative busulfan regimen was found to be effective in reducing nonrelapse mortality without increasing relapse rate for patients undergoing allogeneic hematopoietic cell transplantation, especially for older patients and those with comorbidities.
Article
Hematology
A. Birgitta Versluijs, Coco C. H. de Koning, Arjan C. Lankester, Stefan Nierkens, Wouter J. Kollen, Dorine Bresters, Caroline A. Lindemans, Jaap Jan Boelens, Marc Bierings
Summary: This study prospectively investigated the use of clofarabine-fludarabine-busulfan (CloFluBu) conditioning in allogeneic hematopoietic cell therapy, showing limited toxicity and encouraging event-free survival (EFS). The median age of all patients was approximately 9.7 years, with a 2-year EFS of 72.0% in acute lymphoid leukemia patients and 62.4% in acute myeloid leukemia patients.
Article
Biochemistry & Molecular Biology
Mark-Alexander Schwarzbich, Hao Dai, Lambros Kordelas, Dietrich W. Beelen, Aleksandar Radujkovic, Carsten Mueller-Tidow, Peter Dreger, Thomas Luft
Summary: The study demonstrates that pre-conditioning serum Leptin levels can serve as an independent prognostic marker for relapse following alloSCT in high-risk acute leukemia patients, particularly those in the intermediate to advanced stages. This effect was validated in an independent cohort, suggesting the potential utility of serum Leptin for predicting post-transplant outcomes in certain patient populations.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Biophysics
Borje S. Andersson, Peter F. Thall, Junsheng Ma, Benigno C. Valdez, Roland Bassett, Julianne Chen, Sairah Ahmed, Amin Alousi, Qaiser Bashir, Stefan Ciurea, Alison Gulbis, Rita Cool, Jitesh Kawedia, Chitra Hosing, Partow Kebriaei, Steve Kornblau, Alan Myers, Betul Oran, Katayoun Rezvani, Nina Shah, Elizabeth Shpall, Simrit Parmar, Uday R. Popat, Yago Nieto, Richard E. Champlin
Summary: Pretransplant conditioning with Fludarabine-Busulfan is safe, but clofarabine has improved antileukemic activity. This study aimed to evaluate the efficacy of Flu+Clo-Bu (FCB) compared to Flu-Bu in AML/MDS patients undergoing allogeneic transplantation. The results showed that FCB had a lower relapse incidence but higher non-relapse mortality compared to Flu-Bu. FCB showed improved disease control in NCR patients with low HCT-CI scores. Confirmatory trials are needed to further assess the effectiveness of FCB.
BONE MARROW TRANSPLANTATION
(2022)
Article
Hematology
Gheath Alatrash, Chantal Saberian, Roland Bassett, Peter F. Thall, Celina Ledesma, Yoshimi Lu, May Daher, Benigno C. Valdez, Jitesh Kawedia, Uday Popat, Rohtesh Mehta, Betul Oran, Yago Nieto, Amanda Olson, Paolo Anderlini, David Marin, Chitra Hosing, Amin M. Alousi, Elizabeth J. Shpall, Gabriela Rondon, Julianne Chen, Muzaffar Qazilbash, Richard E. Champlin, Partow Kebriaei
Summary: This study examined the long-term outcomes of adding vorinostat to the conditioning regimen for allogeneic hematopoietic stem cell transplantation. The results showed that there was no benefit in adding vorinostat to the standard regimen for high-risk leukemia patients.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Medicine, Research & Experimental
Sima Jeha, Hiroaki Goto, Andre Baruchel, Emmanuelle Boelle-Le Corfec, Christine Geffriaud-Ricouard, Rob Pieters, Hee Young Shin
Summary: A meta-analysis of patient-level data was conducted to evaluate the clinical benefit of clofarabine monotherapy in the treatment of relapsed or refractory acute lymphoblastic leukemia (R/R ALL). The results showed that the complete remission (CR) rate and overall remission (OR) rate were slightly higher in pediatric patients compared to the overall population. The duration of response and median overall survival (OS) were also longer in pediatric patients who achieved remission. The study supported the use of clofarabine monotherapy in its approved indication and identified no new safety concerns.
ADVANCES IN THERAPY
(2023)
Article
Oncology
Dominic Schenone, Jeffrey R. Andolina, Brooks Rademacher, Thomas J. Fountaine, Elena Edwards, Leti Nunez, Michelle Qiu, Sonakshi Sharma, Craig A. Mullen
Summary: The study suggests that cytokines and cyclosporine may play a significant role in mediating the graft versus leukemia effect. ALL cells exposed to cytokines and cyclosporine remained susceptible to T and NK cell killing, and also showed increased cell death even without exposure to killer cells.
ANTICANCER RESEARCH
(2021)
Article
Oncology
Benigno C. Valdez, Bin Yuan, David Murray, Jeremy Leon Ramdial, Yago Nieto, Uday Popat, Xiaowen Tang, Borje S. Andersson
Summary: Combinations of nucleoside analog(s) and DNA alkylating agent(s) are used for cancer treatment. This study found that adding the HDAC inhibitor SAHA and the PARP inhibitor olaparib to the established drug combination can enhance the cytotoxicity of AML cells.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Yiwen Ling, Na Xu, Ke Zhao, Lijie Han, Qing Zhang, Zhiping Fan, Fen Huang, Zhuowen Chen, Li Xuan, Hui Liu, Jun Xu, Xiaoxia Chen, Sijian Yu, Hongsheng Zhou, Jing Sun, Qifa Liu
Summary: Emerging evidence suggests that CDKN2 deletion may be a poor prognostic predictor in adult B-ALL. Adult B-ALL patients with CDKN2 deletion may benefit from allogeneic hematopoietic cell transplant.
Article
Hematology
Matthew P. Connor, Alison W. Loren, Elizabeth O. Hexner, Mary Ellen Martin, Saar I. Gill, Selina M. Luger, James K. Mangan, Alexander E. Perl, Shannon R. McCurdy, Keith W. Pratz, Colleen Timlin, Craig W. Freyer, Alison Carulli, Christopher Catania, Jacqueline Smith, Lauren Hollander, Alexis M. Zebrowski, Edward A. Stadtmauer, David L. Porter, Noelle Frey
Summary: Patients with refractory or relapsed and refractory myeloid malignancies have a poor prognosis. The use of a myeloablative conditioning regimen combining clofarabine with busulfan has shown antileukemic activity with acceptable toxicity in patients under 70 years old. This study evaluates the clinical outcomes of patients with active myeloid malignancies undergoing allogeneic hematopoietic cell transplantation (HCT) with the clofarabine-busulfan regimen, and concludes that it is an effective transplantation strategy, particularly for patients with advanced myelodysplastic syndrome (MDS).
TRANSPLANTATION AND CELLULAR THERAPY
(2023)
Article
Oncology
Bhagirathbhai Dholaria, Myriam Labopin, Jaime Sanz, Annalisa Ruggeri, Jan Cornelissen, Helene Labussiere-Wallet, Didier Blaise, Edouard Forcade, Patrice Chevallier, Anna Grassi, Ludmila Zubarovskaya, Jurgen Kuball, Patrice Ceballos, Fabio Ciceri, Frederic Baron, Bipin N. Savani, Arnon Nagler, Mohamad Mohty
Summary: This study compared the outcomes of CBT and single-allele-mismatched MMUD allo-HCT with PTCy in acute myeloid leukemia. The results showed that CBT was associated with higher incidence of graft failure and non-relapse mortality compared to MMUD, leading to lower leukemia-free survival, overall survival, and GVHD-free, relapse-free survival. In conclusion, MMUD allo-HCT with PTCy may be a preferred choice over CBT for patients without a fully matched donor.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Article
Oncology
Betul Oran, Rima M. Saliba, Rohtesh S. Mehta, Amin M. Alousi, David Marin, Ben C. Valdez, Julianne Chen, Qaiser Bashir, Stefan O. Ciurea, Amanda L. Olson, Chitra Hosing, Partow Kebriaei, Katy Rezvani, Elizabeth J. Shpall, Richard E. Champlin, Borje S. Andersson, Uday R. Popat
Summary: Fractionated busulfan treatment in patients with AML or myelodysplastic syndrome improves progression-free survival and overall survival without increasing nonrelapse mortality, compared to nonfractionated lower dose regimens.
Review
Immunology
Justin Loke, Richard Buka, Charles Craddock
Summary: While most AML patients achieve complete remission with intensive chemotherapy, many face a risk of relapse if treated with chemotherapy alone. Allogeneic stem cell transplant has become a key treatment strategy for AML patients, especially for those in first complete remission and advanced stages. Despite a decrease in transplant-related mortality, there remains a need to address the risk of disease relapse.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Matthias Limbach, Rea Kuehl, Peter Dreger, Thomas Luft, Friederike Rosenberger, Nikolaus Kleindienst, Birgit Friedmann-Bette, Andrea Bondong, Martin Bohus, Joachim Wiskemann
Summary: The study found that cardiorespiratory fitness (CRF) prior to allogeneic stem cell transplantation (allo-HSCT) is influenced by various factors such as age, gender, body mass index, number of cardiotoxic therapies, hemoglobin level, and physical activity. Patients with decreased CRF may benefit the most from prehabilitative exercise.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Hematology
Premal D. Lulla, Swati Naik, Spyridoula Vasileiou, Ifigeneia Tzannou, Ayumi Watanabe, Manik Kuvalekar, Suhasini Lulla, George Carrum, Carlos A. Ramos, Rammurti Kamble, LaQuisa Hill, Jasleen Randhawa, Stephen Gottschalk, Robert Krance, Tao Wang, Mengfen Wu, Catherine Robertson, Adrian P. Gee, Betty Chung, Bambi Grilley, Malcolm K. Brenner, Helen E. Heslop, Juan F. Vera, Ann M. Leen
Summary: Leukemia-specific T cells (mLSTs) selectively recognized and killed leukemia antigen-pulsed cells in vitro, showing no activity against recipient's normal cells. Infusions of mLSTs were well tolerated with no severe GVHD, leading to antileukemia effects and promising outcomes for AML/MDS patients after HCT.